Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
University of Tennessee Cancer Institute at Methodist Central Hospital
mi
from
Memphis, TN
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
University of Tennessee Cancer Institute at Methodist Central Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Harrington Cancer Center
mi
from
Amarillo, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Amarillo
mi
from
Amarillo, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
University of Texas Medical Branch
mi
from
Galveston, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
CCOP - Scott and White Hospital
mi
from
Temple, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
CCOP - Scott and White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Puget Sound Oncology Consortium
mi
from
Seattle, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Puget Sound Oncology Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
CCOP - Northwest
mi
from
Tacoma, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated:  10/26/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated: 10/26/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated:  10/26/2015
Bellevue Hospital Center (NYU Langone Medical Center affiliate)
mi
from
New York, NY
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated: 10/26/2015
Bellevue Hospital Center (NYU Langone Medical Center affiliate)
mi
from
New York, NY
Click here to add this to my saved trials
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated:  10/27/2015
Montefiore Medical Center
mi
from
Bronx, NY
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated: 10/27/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated:  10/27/2015
NYU Cancer Institute
mi
from
New York, NY
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated: 10/27/2015
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  10/29/2015
Montefiore Medical Center
mi
from
Bronx, NY
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 10/29/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  10/30/2015
Columbia University Medical Center
mi
from
New York, NY
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 10/30/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  10/30/2015
University of Virginia
mi
from
Charlottesville, VA
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 10/30/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  10/30/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 10/30/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Accelerating Gastrointestinal Recovery
Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  10/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Accelerating Gastrointestinal Recovery
Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 10/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer
Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer
Status: Enrolling
Updated:  11/4/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer
Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer
Status: Enrolling
Updated: 11/4/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
University of Colorado Cancer Center at UC Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated:  11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)
Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome
Status: Enrolling
Updated: 11/6/2015
Presbyterian/St. Luke's Medical Center (PSLMC) - Denver Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
Status: Enrolling
Updated:  11/13/2015
University of Pennsylvania, Department of Obstetrics and Gynecology
mi
from
Philadelphia, PA
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
Status: Enrolling
Updated: 11/13/2015
University of Pennsylvania, Department of Obstetrics and Gynecology
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
Status: Enrolling
Updated:  11/13/2015
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
Status: Enrolling
Updated: 11/13/2015
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  11/13/2015
Sharp Memorial Hospital
mi
from
Chula Vista, CA
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 11/13/2015
Sharp Memorial Hospital
mi
from
Chula Vista, CA
Click here to add this to my saved trials
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  11/13/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 11/13/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  11/13/2015
Nationales Centrum fur Tumorerkrandungen
mi
from
Heidelberg,
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 11/13/2015
Nationales Centrum fur Tumorerkrandungen
mi
from
Heidelberg,
Click here to add this to my saved trials
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Burbank, CA
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
New Haven, CT
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Fort Meyers, FL
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Fort Meyers, FL
Click here to add this to my saved trials
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Atlanta, GA
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Boston, MA
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated:  11/18/2015
Investigational Site Number 056002
mi
from
Haine-Saint-Paul,
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
Status: Enrolling
Updated: 11/18/2015
Investigational Site Number 056002
mi
from
Haine-Saint-Paul,
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Abington Memorial Hospital
mi
from
Abington, PA
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Allegiance Health
mi
from
Jackson, MI
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Baystate Medical Center
mi
from
Springfield, MA
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Borgess Medical Center
mi
from
Kalamazoo, MI
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Cadence Cancer Center in Warrenville
mi
from
Warrenville, IL
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Cadence Cancer Center in Warrenville
mi
from
Warrenville, IL
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Case Western Reserve Univ
mi
from
Cleveland, OH
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated:  11/20/2015
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Status: Enrolling
Updated: 11/20/2015
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials